Combinaison thérapeutique innovante pour le diabète type 2 à risque cardiorénal.

Sodium-Glucose Transporter 2 Inhibitors; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Humans; Diabetes Mellitus, Type 2/drug therapy/complications; Sodium-Glucose Transporter 2 Inhibitors/administration & dosage/therapeutic use; Glucagon-Like Peptide-1 Receptor/agonists; Drug Therapy, Combination/methods; Hypoglycemic Agents/administration & dosage/therapeutic use; Cardiovascular Diseases/prevention & control

Abstract :

[en] Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiorenal -prognosis of at-risk patients with type 2 diabetes thanks to pleiotropic effects that are either common or specific. This article discusses the clinical efficacy of a combined therapy with the two medications. Data were obtained from post hoc analyses of subgroups of participants to cardiovascular outcome trials and from real-life observational retro-spective cohort studies. The reported superiority of the combination versus either monotherapy should be confirmed in an ongoing large prospective trial (PRECIDENTD). The extra-cost of such a combined therapy as well as the common underuse of each pharmacological class in daily clinical practice deserve attention.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology
Urology & nephrology
Cardiovascular & respiratory systems

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques

Paquot, Nicolas ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladies métaboliques

Language :

French

Title :

Combinaison thérapeutique innovante pour le diabète type 2 à risque cardiorénal.

Alternative titles :

[en] Innovative therapeutic drug combination for type 2 diabetes at cardiorenal risk.

Publication date :

28 August 2024

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Chêne-Bourg, Ch

Volume :

Issue :

884

Pages :

1492-1497

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 04 December 2024

Statistics

Number of views

28 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021 Apr;46:101102.
Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 Oct;16(10):556-77.
Scheen AJ. Protection cardiorénale avec les inhibiteurs des SGLT2: d’EMPAREG OUTCOME à VERTIS CV. Rev Med Suisse. 2020 Aug 26;16(703):1483-8.
Scheen AJ. Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract. 2018 Sep;143:88-100.
Giugliano D, Scappaticcio L, Longo M, Bellastella G, Esposito K. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off. Cardiovasc Diabetol. 2021 Oct 12;20(1):205.
Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021 Jan 13;372:m4573.
Scheen AJ, Paquot N. Inhibiteur des SGLT2 ou analogue du GLP-1 chez un patient diabetique avec maladie cardiovasculaire? Rev Med Suisse. 2018 Aug 22;14(615):1460-5.
Scheen AJ. Combinaison «inhibiteur des SGLT2-agoniste des récepteurs du GLP-1» pour traiter le diabète de type 2. Rev Med Suisse. 2019 Aug 21;15(659):1436-41.
Li C, Luo J, Jiang M, Wang K. The Efficacy And Safety Of The Combination Therapy With Glp-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Front Pharmacol. 2022 Feb 4;13:838277.
Singh AK, Singh R. Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. World J Cardiol. 2022 Jun 26;14(6):329-42.
Clegg LE, Penland RC, Bachina S, et al. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovasc Diabetol. 2019 Oct 22;18(1):138.
Lam CSP, Ramasundarahettige C, Branch KRH, et al. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O trial. Circulation. 2022 Feb 22;145(8):565-74.
Neves JS, Borges-Canha M, Vasques-Nóvoa F, et al. GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes. J Am Coll Cardiol. 2023 Aug 8;82(6):517-25.
Arnott C, Neuen BL, Heerspink HJL, et al. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. Int J Cardiol. 2020 Nov 1;318:126-9.
Cahn A, Wiviott SD, Mosenzon O, et al. Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58. Diabetes Obes Metab. 2021 Jan;23(1):29-38.
Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020 Oct 8;383(15):1425-35.
Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021 Jan 14;384(2):129-39.
Scheen AJ. GLP-1 RA and SGLT2i in type 2 diabetes: pleiotropic cardiometabolic effects and add-on value of a combined therapy. Drugs. 2024: in press.
Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024 May 24. DOI: 10.1056/NEJMoa2403347.
Ahmad A, Sabbour H. Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies. Cardiovasc Diabetol. 2024 Mar 18;23(1):99.
Jensen MH, Kjolby M, Hejlesen O, Jakobsen PE, Vestergaard P. Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, And All-Cause Mortality For Widely Used Antihyperglycemic Dual And Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users. Diabetes Care. 2020 Jun;43(6):1209-18.
Riley DR, Essa H, Austin P, et al. All-cause mortality and cardiovascular outcomes with sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes Obes Metab. 2023 Oct;25(10):2897-909.
Wright AK, Carr MJ, Kontopantelis E, et al. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Diabetes Care. 2022 Apr 1;45(4):909-18.
Simms-Williams N, Treves N, Yin H, et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ. 2024 Apr 25;385:e078242.
Scheen AJ. Clinical pharmacology of antidiabetic drugs: What can be expected of their use? Presse Med. 2023 Mar;52(1):104158.
Scheen AJ. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favourable benefit-safety profile. Expert Opin Drug Saf. 2024 May 13:1-4. DOI: 0.1080/14740338.2024.2354885.
Scheen AJ. Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease. Diabetes Epidemiol Manag. 2024 Apr-Jun;14:100197.
Scheen AJ. Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk. Diabetes Epidemiol Manag. 2024 Jan-Mar;13:100184.
Scheen AJ. Sous-utlisation des gliflozines chez les patients à haut risque cardiorénal. Rev Med Suisse. 2024;20:1498-502.
Scheen AJ. Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized? Expert Rev Clin Pharmacol. 2023 Jul-Dec;16(11):1053-62.